Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
2024年8月1日 - 8:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its second quarter
2024 financial results on Thursday, August 8, 2024 and will provide
a business update.
Altimmune management will host a conference call
at 8:30 am E.T. on August 8 to discuss financial results and
provide a business update. The conference call will be webcast live
on Altimmune’s Investor Relations website at
https://ir.altimmune.com/investors.
Participants who would like to join the call may
register here to receive the dial-in numbers and unique PIN to
access the call. Shortly after the call, a replay will be available
on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Vipin
GargPresident and Chief Executive OfficerPhone:
240-654-1450ir@altimmune.com
Investor Contacts:Lee RothBurns
McClellanPhone: 646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle
CanteyInizio Evoke, Biotech Phone:
619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 9 2024 まで 10 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 10 2023 まで 10 2024